Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PharmaCyte Biotech, Inc. - Common Stock (NQ:PMCB)

0.9608 +0.0251 (+2.68%)
Streaming Delayed Price Updated: 1:34 PM EDT, Aug 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PharmaCyte Biotech, Inc. - Common Stock

< Previous 1 2 3 4 Next >
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (... 
Via Benzinga
77 Biggest Movers From Yesterday
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares surged 65.4% to close at $2.10 on Thursday after the company announced it is expanding its blockchain business to... 
Via Benzinga
PharmaCyte Biotech Announces Closing of $15-Million Public Offering
From PharmaCyte Biotech, Inc.
Via Business Wire
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Uplist to The Nasdaq Capital Market and Launch of Public Offering
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Update on Study Progress and Uplist to Nasdaq
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Stability Test Results on Cells from Master Cell Bank
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Stability Test Results on Cells from Master Cell Bank
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Reverse Stock Split
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Results of Vote at Annual Meeting of Stockholders
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Provides Update on Status of Activities to Lift Clinical Hold
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Shareholders Vote to Increase the Authorized Capital
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Adjournment of Annual Meeting of Stockholders, Recording of Stockholder Meeting Available
From PharmaCyte Biotech, Inc.
Via Business Wire
PharmaCyte Biotech Announces Details to Attend This Week’s Virtual Annual Meeting of Shareholders
From PharmaCyte Biotech, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.